Sxr, A Novel Target for Breast Cancer Therapeutics
Abstract
One of the major challenges in breast cancer research is to develop new chemotherapeutic and chemopreventive agents particularly for non-estrogen dependent and drug-resistant estrogen dependent breast cancers. SXR activators were able to cause cell cycle arrest and apoptosis in ER and ER breast cancer cell lines in culture. Different SXR activators caused accumulation of p53 in ER breast cancer cells leading to increase in its target genes involved in apoptosis and cell cycle. Confirmation of these results in at least two ER breast cancer cell lines suggests validity of this model in estrogen dependent breast cancer. Establishment of loss of function studies in these cell lines confirmed the significance and requirement of SXR in these compounds led apoptosis. Moreover loss of function studies and microarray studies on estroger receptor negative cells lines in next year of funding will be able to establish the role of SXR as apoptosis inducer in estrogen receptor independent cells and its mechanism of action in these cell lines. This will provide opportunities for rational drug design and improvement of the efficacy of existing drugs that act through SXR.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 30, 2008
- Accession Number
- ADA486068
Entities
People
- Suman Verma
Organizations
- University of California, Irvine